NCT02507583View on ClinicalTrials.gov

Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

September 1, 2015

Primary Completion Date

March 6, 2018

Study Completion Date

August 17, 2020

Conditions
Malignant GliomaNeoplasms
Interventions
DRUG

IGF-1R/AS ODN; Surgery with tissue harvest and implantation 20 diffusion chambers in the rectus sheath with IGF-1R/AS ODN within 24 hours of craniotomy, implanted for 48 hours.

Trial Locations (1)

19107

Thomas Jefferson University Hospital, Philadelphia

All Listed Sponsors
lead

david andrews

OTHER

NCT02507583 - Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma | Biotech Hunter | Biotech Hunter